Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theratope STn-KLH vaccine
- Development stage
- Phase 3
- Lead developer
- Merck KGaA
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Theratope STn-KLH vaccine is an investigational therapeutic cancer vaccine developed as an active specific immunotherapy. It consists of a synthetic sialyl-Tn (STn) carbohydrate antigen conjugated to keyhole limpet hemocyanin (KLH), a high molecular weight protein carrier. The STn antigen mimics a tumor-associated carbohydrate found on the MUC1 mucin of many human adenocarcinoma cells, including breast, ovarian, colorectal, gastric, and pancreatic cancers. The mechanism involves stimulating both humoral and cellular immune responses against the tumor-associated antigen to inhibit tumor growth and potentially improve survival outcomes in patients with advanced cancers. Clinical development focused primarily on metastatic breast cancer; while the vaccine was well-tolerated with minimal toxicity (mainly local injection site reactions), pivotal phase III trials did not meet their primary efficacy endpoints[1][2][6][8].
- Brand names
- Theratope
- Other names
- Sialyl-Tn-KLH vaccineSTn-keyhole limpet hemocyanin vaccine
02
Targets
STn-MUC1 (Sialyl-Tn-MUC1)
Beyond the preview
Go deeper on Theratope STn-KLH vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Theratope STn-KLH vaccine.